Indapta Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-14.
Indapta Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 14, 2025. The filing reports $50.80M sold. Its industry group is Other Technology. It names Mark Frohlich (Executive Officer, Director), Ronald Martell (Director), Lori Hu (Director) (SEC Form D, October 14, 2025).
Is this your company?
Sell to companies like Indapta Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Indapta Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Indapta Therapeutics Inc., from the filings we hold.
Other Technology raises by companies based in Texas, filed in October 2025, largest first.
Get an email when Indapta Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Indapta Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Indapta Therapeutics Inc. →Get the full cited report on Indapta Therapeutics Inc.
What the filing shows about Indapta Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Indapta Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Indapta Therapeutics Inc.'s address as 5000 Gulf Fwy. Building 4, Room 118, Houston, TX 77023.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Indapta Therapeutics Inc. See pricing
Indapta Therapeutics Inc. is a registered filer with the SEC (CIK 1910175) and has filed since 2025-10-14. 1 filing is on record, the latest on 2025-10-14.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Indapta Therapeutics Inc.'s Form D of 2025-10-14 names Mark Frohlich, Ronald Martell, Lori Hu and 1 more as its officers, directors or promoters.
Its new offerings report $50.80M sold across 1 offering, as its own filings state.
Trailing twelve months. 3844 filings in Other Technology, totalled by week.
Mark Frohlich is named as Executive Officer and Director on the Form D that Indapta Therapeutics Inc. filed with the SEC on 14 October 2025, one of 4 people that filing names.
Ronald Martell is named as Director on the Form D that Indapta Therapeutics Inc. filed with the SEC on 14 October 2025, one of 4 people that filing names.
Lori Hu is named as Director on the Form D that Indapta Therapeutics Inc. filed with the SEC on 14 October 2025, one of 4 people that filing names.
Fabio Pucci is named as Director on the Form D that Indapta Therapeutics Inc. filed with the SEC on 14 October 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-10-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Indapta Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Indapta Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indapta Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Indapta Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Indapta Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Indapta Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in Houston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/indapta-therapeutics-inc-form-d-25000001